Hangzhou Century (SZSE:300078) Adds CN¥480m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 72%
Hangzhou Century (SZSE:300078) Adds CN¥480m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 72%
Hangzhou Century Co., Ltd (SZSE:300078) shareholders will doubtless be very grateful to see the share price up 60% in the last quarter. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Indeed, the share price is down a whopping 72% in that time. The recent bounce might mean the long decline is over, but we are not confident. The important question is if the business itself justifies a higher share price in the long term.
思創醫惠股份有限公司(SZSE:300078)的股東無疑會非常感激,在最後一個季度股票價格上漲了60%。但是,這能否彌補過去5年下降帶來的所有創傷呢?不太可能。事實上,在這段時間內,股價暴跌了72%。最近的反彈可能意味着長期的下跌已經結束,但我們並不自信。關鍵問題是,這個業務本身是否在長期內能證明其股票價格更高的價值。
The recent uptick of 14% could be a positive sign of things to come, so let's take a look at historical fundamentals.
最近14%的反彈可能是有望好轉的積極跡象,因此讓我們看一下歷史基本面。
Hangzhou Century isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
思創醫惠目前並未盈利,因此大多數分析師會關注營業收入的增長,以了解基礎業務的增長速度。無盈利公司的股東通常渴望強勁的營業收入增長。這是因爲,如果營業收入增長微不足道且從未盈利,就很難對公司的可持續性感到信心。
In the last five years Hangzhou Century saw its revenue shrink by 14% per year. That's definitely a weaker result than most pre-profit companies report. So it's not altogether surprising to see the share price down 11% per year in the same time period. This kind of price performance makes us very wary, especially when combined with falling revenue. Ironically, that behavior could create an opportunity for the contrarian investor - but only if there are good reasons to predict a brighter future.
在過去五年中,思創醫惠的營業收入每年萎縮14%。這絕對是一個比大多數未盈利公司報告的結果要弱的。因此,在同一時期內看到股價每年下降11%也就不足爲奇了。這種價格表現讓我們非常警惕,尤其是在營業收入下滑的情況下。具有諷刺意味的是,這種行爲可能爲逆勢投資者創造機會——但前提是有充分的理由預測更光明的未來。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的圖表顯示了收益和營收隨時間的變化情況(通過單擊圖像揭示確切的值)。
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
你可以在這個免費的互動圖表中看到它的資產負債表如何隨着時間的推移而加強(或削弱)。
A Different Perspective
另一種看法
Hangzhou Century shareholders are down 21% for the year, but the market itself is up 4.9%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. However, the loss over the last year isn't as bad as the 11% per annum loss investors have suffered over the last half decade. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. It's always interesting to track share price performance over the longer term. But to understand Hangzhou Century better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Hangzhou Century you should be aware of, and 1 of them is a bit unpleasant.
思創醫惠的股東今年下跌了21%,但市場本身上漲了4.9%。即使是好股票的股價有時也會下跌,但在我們過於關注之前,我們希望看到業務的基本指標有所改善。然而,過去一年的損失並不像過去五年投資者每年11%的損失那麼嚴重。我們希望有明確的信息表明公司將會增長,然後再考慮股價會穩定的觀點。長期跟蹤股價表現總是很有趣的。但爲了更好地了解思創醫惠,我們需要考慮許多其他因素。一個例子:我們發現思創醫惠有3個你應該知道的警告信號,其中1個有點不太愉快。
If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.
如果您和我一樣,那麼您一定不想錯過這份免費的被內部人員買入的低估小盤股清單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文中引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。